Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has raised RMB 200 million (USD 27.6 million) in a Series B financing round. The round was led by New Alliance Capital, with participation from Lingang Group’s healthcare industry fund, GF Capital, and a “famous multinational life science company.” The proceeds will be used to advance the company’s research and development platform and expand its offerings in gene therapy and other biotechnology fields.
Company Background and Innovation
Founded in 2018, Kactus Biosystems is known for its Structure Aided design and Multiplex Screening (SAMS) platform, which focuses on the research and development of functional recombinant proteins and antibodies. In the field of gene therapy, Kactus Bio provides the only domestic GMP-compliant Cas9 enzyme that meets the clinical needs of gene editing. The company also offers versatile nucleases for the AAV and vaccine industries, GMP cytokines for cell therapy, and high-yield T7 transcriptase and capping enzymes for mRNA vaccine production.
Previous Financing and Future Outlook
Kactus Bio has previously closed four financing rounds, backed by investors such as Divine Capital, SDIC Venture Capital, Sherpa Healthcare Partners, 3E Bioventures, and TF Capital, alongside strategic partners Biocytogen and Abogen Bio. With the new Series B funding, Kactus Biosystems aims to further enhance its technological capabilities and market position, driving innovation in the biotechnology sector.-Fineline Info & Tech
